Zogenix announced that it will present new FINTEPLA? (fenfluramine) data from eight abstracts at the American Epilepsy Society (AES) Annual Meeting, taking place from December 3-7, 2021, in Chicago, IL. The Company will also have an additional four posters in a virtual scientific exhibition room and is sponsoring the Better Outcomes Through Diversity poster session during AES 2021. Full data for the posters presented in the main conference will be available on the AES 2021 conference site beginning on Friday, December 3, 2021, at 9:00 AM Central Time, and will also be available following AES on the Zogenix Newsroom site. Authors will be available to discuss their data with attendees during the following times: Fenfluramine (Fintepla?) Treatment Improves Everyday Executive Functioning in Preschool Children With Dravet Syndrome: Analysis From 2 Pooled Phase 3 Clinical Trials Bishop, Isquith, Gioia, et al. Poster #2.413. Authors available: December 5, 2021, 12:00 ? 2:00 PM CT. Fenfluramine (Fintepla?) Significantly Reduces Day-to-Day Seizure Burden by Increasing Seizure-Free Days: A Time-to-Event Analysis of a Phase 3 Study in Dravet Syndrome Sullivan, Specchio, Devinsky, et al. Poster #3.280. Authors available: December 6, 2021, 12:00 ? 1:45 PM CT. Serial Echocardiographic Assessment of Patients with Dravet Syndrome Treated with Fenfluramine (Fintepla?) for up to 3 years: No incidence of Valvular Heart Disease or Pulmonary Artery Hypertension Agarwal, Farfel, Gammaitoni, et al. Poster #3.415. Authors available: December 6, 2021, 12:00 ? 1:45 PM CT. Fenfluramine (Fintepla?) Provides Clinically Meaningful and Durable Improvement in Seizure Frequency in Patients With Dravet Syndrome Regardless of Age: ?Real-World? Use in a European Early Access Program Guerrini, Specchio, Aledo-Serrano, et al. Poster #1.298. Authors available: December 4, 2021, 12:00 ? 2:00 PM CT. Fenfluramine Directly Inhibits Cortical Spreading Depolarization?A Pathophysiologic Process Linked to SUDEP Ning, Reeder, Noebels, et al. Poster #3.394. Authors available: December 6, 2021, 12:00 ? 1:45 PM CT. Fenfluramine Exhibits Disease-Modifying Effects in a Mouse Model of Dravet Syndrome Reeder, Cha, Filatov, et al. Poster #3.392. Authors available: December 6, 2021, 12:00 ? 1:45 PM CT. Dual Activity of Fenfluramine (Fintepla?) as a Serotonin Receptor Agonist and Positive Sigma-1 Receptor Modulator: Implication for Disease Modification in Developmental and Epileptic Encephalopathies Reeder, Martin, Sourbron, et al. Poster #3.393. Authors available: December 6, 2021, 12:00 ? 1:45 PM CT. Sleep Disturbance in Parents of Individuals with Epileptic Encephalopathy Salem, Amtmann, Bamer, et al. Poster #2.371. Authors available: December 5, 2021, 12:00 ? 2:00 PM CT. Scientific Exhibit Room. All eight posters from the main conference above, plus four additional Scientific Exhibit Room posters, will be available in the Zogenix Scientific Exhibit Room. Questions regarding data in the Scientific Exhibition Room will be answered during a live discussion on December 5, 2021, 8:00 AM ? 1:00 PM Central Time. Fenfluramine (Fintepla?) provides prolonged periods of seizure-free days in patients with Dravet syndrome: using a time-to-event analysis to measure treatment effect. Sullivan, Specchio, Devinksky, et al. Fenfluramine (Fintepla?) provides clinically meaningful reduction in frequency of seizures resulting in a drop in patients with Lennox-Gastaut syndrome for up to 1 year: interim analysis of an open-label extension study. Knupp, Scheffer, Ceulemans, et al. Fenfluramine (Fintepla?) Treatment Improves Everyday Executive Functioning in Patients With Lennox-Gastaut Syndrome: Analysis From a Phase 3 Clinical Trial. Bishop, Isquith, Gioia, et al. Impact of Fenfluramine (Fintepla?) on the expected SUDEP mortality rates in patients with Dravet syndrome. Cross, Galer, Gil-Nagel, et al. Zogenix is sponsoring the Better Outcomes Through Diversity poster session, which will be held on December 5, 2021, from 5:15 p.m. to 6:15 p.m. Central Time. The event will feature 50 posters on research by and/or about individuals from underrepresented minority groups.